It is great to hear RapiMeds being discussed again with such enthusiasm. With Compounding, RapiMeds, and PIMD, SCRC will be the winner we all knew it would be. Mr. Schneiderman has developed an incredible opportunity for investors who are willing to take advantage of these incredibly low prices. I just wish I had the extra cash to buy right now. The next several months will be worth the wait. I was told Tuscany in September is the best time to visit.